The loss of patent protection for Northera, a core hypotension product, depressed sales at H. Lundbeck A/S in the first half year and also affected its revenue forecast for the year. Partially offsetting this were sales gains for four medicines targeting neurological disorders as healthcare activity gradually recovered from the worst of the pandemic.
